Galidesivir Cleared for Compassionate Use Against Bundibugyo Ebola in Uganda
核心洞察
Island Pharmaceuticals (搜索) received regulatory and ethics approvals for compassionate use of galidesivir in the Bundibugyo Ebola outbreak, with deployment expected in Uganda this year.
Galidesivir is a broad-spectrum antiviral delivered intravenously that blocks viral replication; early healthy-volunteer studies found it generally safe and well tolerated.
The drug will be studied under the WHO's MEURI framework, enabling prospective collection of clinical, safety, and virological data during the public health emergency.
Island Pharmaceuticals (搜索) has received regulatory and ethics approvals to deploy its investigational antiviral galidesivir for compassionate use in patients infected with the Bundibugyo Ebola virus (搜索), the Melbourne-based biotech announced this week. The approvals position galidesivir as a potential treatment for a lethal viral strain that currently has no approved vaccines or therapeutic options.
The drug is expected to be deployed in Uganda this year, giving the company an opportunity to generate "prospective human efficacy, safety and virological data" during an active outbreak. Shares in Island Pharma rose nearly 27% on Australia's ASX exchange following the announcement.
Regulatory clearance and the MEURI framework
Dr. Rony Reginald Bahatungire, acting commissioner of clinical services at Uganda's health ministry, confirmed the decision: "We have issued administrative clearance for deployment of the molecules for compassionate use of Galidesivir — a broad-spectrum antiviral for the treatment of patients infected with Bundibugyo Ebola."
Dr. Charles Olaro, director general of health services at the health ministry, explained that galidesivir is one of several investigational broad-spectrum antiviral medicines included in the Ministry of Health-sponsored adaptive Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) protocol. These medicines may be offered on a compassionate use basis during outbreaks when no approved treatments are available as potential life-saving interventions.
Unlike conventional compassionate use programs, MEURI requires prospective collection of clinical, safety and virological data under an approved protocol, enabling investigators to systematically evaluate patient outcomes while providing access to potentially beneficial investigational therapies.
"The decision to approve this program reflects a rigorous scientific and ethical review process involving Uganda's leading regulatory and public health authorities and provides an important validation of galidesivir's existing body of preclinical and clinical evidence," said Dr. David Foster, Island's chief executive and managing director. "This study represents a rare dual-pathway opportunity to advance galidesivir toward potential approval and future government procurement."
Mechanism and early clinical data
Galidesivir is delivered intravenously and is designed to block viral replication. In early studies with healthy volunteers, the drug was found to be generally safe and well tolerated. Island Pharma noted that concurrent Ebola and Marburg virus activity in Uganda "highlights the growing importance of broad-spectrum antiviral therapies and medical countermeasures, such as galidesivir," and advances the drug across two potential complementary development pathways.
Outbreak context and competing investigational therapies
The Bundibugyo Ebola virus (搜索) outbreak was declared in mid-May in the Democratic Republic of the Congo (DRC), which is thought to be the epicentre. According to WHO figures, the death toll has passed 500, with 1,561 confirmed cases in DRC. In neighboring Uganda, there have been 20 confirmed cases and two deaths. Dr. Olaro said the Ebola situation in Uganda is under control, with the country ending a second week without any new Ebola case. Only two patients remain under treatment and both are expected to be discharged this week.
Dr. Henry Bosa Kyobe, the incident commander at Uganda's health ministry, noted that Uganda is currently also using remdesivir, a sister drug in the same category approved under the adaptive MEURI protocol. Two other potential Bundibugyo Ebola treatments — Mapp Biopharmaceutical (搜索)'s MBP134 and Gilead's remdesivir — recently started human testing in the DRC.
The Bundibugyo strain was first detected between 2007 and 2008 in Uganda's Bundibugyo district, where 149 confirmed cases and 37 deaths were recorded at the time. It was the first new Ebola species identified in decades.